Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.

Wang L, Yang H, Zamperone A, Diolaiti D, Palmbos PL, Abel EV, Purohit V, Dolgalev I, Rhim AD, Ljungman M, Hadju CH, Halbrook CJ, Bar-Sagi D, di Magliano MP, Crawford HC, Simeone DM.

Genes Dev. 2019 Jun 1;33(11-12):641-655. doi: 10.1101/gad.323303.118. Epub 2019 May 2.

PMID:
31048544
2.

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer.

Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS.

Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15.

PMID:
30877085
3.

A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma.

Diolaiti D, Dela Cruz FS, Gundem G, Bouvier N, Boulad M, Zhang Y, Chou AJ, Dunkel IJ, Sanghvi R, Shah M, Geiger H, Rahman S, Felice V, Wrzeszczynski KO, Darnell RB, Antonescu CR, French CA, Papaemmanuil E, Kung AL, Shukla N.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003194. doi: 10.1101/mcs.a003194. Print 2018 Dec.

4.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A.

Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18.

5.

PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Efimenko E, Davé UP, Lebedeva IV, Shen Y, Sanchez-Quintero MJ, Diolaiti D, Kung A, Lannutti BJ, Chen J, Realubit R, Niatsetskaya Z, Ten V, Karan C, Chen X, Califano A, Diacovo TG.

Mol Cancer Ther. 2017 Oct;16(10):2069-2082. doi: 10.1158/1535-7163.MCT-17-0141. Epub 2017 Jul 17.

6.

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.

Hsiao SJ, Karajannis MA, Diolaiti D, Mansukhani MM, Bender JG, Kung AL, Garvin JH Jr.

Cold Spring Harb Mol Case Stud. 2017 Mar;3(2):a001396. doi: 10.1101/mcs.a001396.

7.

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.

8.

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.

Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL.

Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0.

9.

A novel role for the extended MYC network in cancer cell survival.

Carroll PA, Diolaiti D.

Mol Cell Oncol. 2015 Apr 14;3(1):e1026528. doi: 10.1080/23723556.2015.1026528. eCollection 2016 Jan.

10.

Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.

Carroll PA, Diolaiti D, McFerrin L, Gu H, Djukovic D, Du J, Cheng PF, Anderson S, Ulrich M, Hurley JB, Raftery D, Ayer DE, Eisenman RN.

Cancer Cell. 2015 Feb 9;27(2):271-85. doi: 10.1016/j.ccell.2014.11.024. Epub 2015 Jan 29.

11.

Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

Diolaiti D, McFerrin L, Carroll PA, Eisenman RN.

Biochim Biophys Acta. 2015 May;1849(5):484-500. doi: 10.1016/j.bbagrm.2014.05.016. Epub 2014 May 22. Review.

12.

c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.

Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, Martinelli G, Perini G.

Mol Cancer Res. 2011 Aug;9(8):1054-66. doi: 10.1158/1541-7786.MCR-10-0510. Epub 2011 Jun 21.

13.

Premetazoan ancestry of the Myc-Max network.

Young SL, Diolaiti D, Conacci-Sorrell M, Ruiz-Trillo I, Eisenman RN, King N.

Mol Biol Evol. 2011 Oct;28(10):2961-71. doi: 10.1093/molbev/msr132. Epub 2011 May 13.

14.

A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.

Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, Perini G.

Cancer Res. 2011 Jan 15;71(2):404-12. doi: 10.1158/0008-5472.CAN-10-2627. Epub 2010 Dec 1.

15.

Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis.

Conerly ML, Teves SS, Diolaiti D, Ulrich M, Eisenman RN, Henikoff S.

Genome Res. 2010 Oct;20(10):1383-90. doi: 10.1101/gr.106542.110. Epub 2010 Aug 13.

16.

Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells.

Porro A, Haber M, Diolaiti D, Iraci N, Henderson M, Gherardi S, Valli E, Munoz MA, Xue C, Flemming C, Schwab M, Wong JH, Marshall GM, Della Valle G, Norris MD, Perini G.

J Biol Chem. 2010 Jun 18;285(25):19532-43. doi: 10.1074/jbc.M109.078584. Epub 2010 Mar 16.

17.

Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.

Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, Diolaiti D, Della Valle G, Perini G, Marshall GM.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18682-7. Epub 2007 Nov 14. Erratum in: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):21021.

18.

Functional cooperation between TrkA and p75(NTR) accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities.

Diolaiti D, Bernardoni R, Trazzi S, Papa A, Porro A, Bono F, Herbert JM, Perini G, Della Valle G.

Exp Cell Res. 2007 Aug 15;313(14):2980-92. Epub 2007 Jun 19.

PMID:
17619016
19.

p14ARF interacts with N-Myc and inhibits its transcriptional activity.

Amente S, Gargano B, Diolaiti D, Della Valle G, Lania L, Majello B.

FEBS Lett. 2007 Mar 6;581(5):821-5. Epub 2007 Feb 2.

20.

In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation.

Perini G, Diolaiti D, Porro A, Della Valle G.

Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12117-22. Epub 2005 Aug 10.

21.

In vivo functional dissection of human inner kinetochore protein CENP-C.

Trazzi S, Bernardoni R, Diolaiti D, Politi V, Earnshaw WC, Perini G, Della Valle G.

J Struct Biol. 2002 Oct-Dec;140(1-3):39-48.

PMID:
12490152

Supplemental Content

Loading ...
Support Center